

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

## SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ivermectin / Abamectin Liquid Formulation

**Manufacturer or supplier's details**

Company name of supplier	: MSD
Address	: 126 E. Lincoln Avenue Rahway, New Jersey U.S.A. 07065
Telephone	: 908-740-4000
Emergency telephone	: 1-908-423-6000
E-mail address	: EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use	: Veterinary product
Restrictions on use	: Not applicable

## SECTION 2. HAZARDS IDENTIFICATION

**GHS Classification**

Acute toxicity (Oral)	: Category 4
Acute toxicity (Inhalation)	: Category 4
Skin corrosion/irritation	: Category 2
Serious eye damage/eye irritation	: Category 2A
Reproductive toxicity	: Category 1B
Specific target organ toxicity - single exposure (Oral)	: Category 1 (Central nervous system)
Specific target organ toxicity - single exposure	: Category 3
Specific target organ toxicity - repeated exposure (Oral)	: Category 1 (Central nervous system)
Specific target organ toxicity - repeated exposure	: Category 2 (Central nervous system)

**GHS label elements**

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H302 + H332 Harmful if swallowed or if inhaled.  
H315 Causes skin irritation.

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

H319 Causes serious eye irritation.  
H335 May cause respiratory irritation.  
H360Df May damage the unborn child. Suspected of damaging fertility.  
H370 Causes damage to organs (Central nervous system) if swallowed.  
H372 Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.  
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

## Precautionary Statements

:

**Prevention:**

P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe mist or vapors.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P271 Use only outdoors or in a well-ventilated area.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell. Rinse mouth.  
P302 + P352 IF ON SKIN: Wash with plenty of water.  
P304 + P340 + P312 IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Call a POISON CENTER or doctor/ physician if you feel unwell.  
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.  
P332 + P313 If skin irritation occurs: Get medical advice/ attention.  
P337 + P313 If eye irritation persists: Get medical advice/ attention.  
P362 + P364 Take off contaminated clothing and wash it before reuse.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

## Ivermectin / Abamectin Liquid Formulation

Version 7.2      Revision Date: 03.02.2025      SDS Number: 1210013-00024      Date of last issue: 30.09.2023  
Date of first issue: 10.01.2017

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
N-Methyl-2-pyrrolidone	872-50-4	$\geq 20$ -< 30
Ivermectin	70288-86-7	$\geq 1$ -< 5
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	$\geq 1$ -< 5
(dl)-a-Tocopheryl acetate	7695-91-2	< 0.1

**SECTION 4. FIRST AID MEASURES**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
If not breathing, give artificial respiration.  
If breathing is difficult, give oxygen.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.  
Never give anything by mouth to an unconscious person.
- Most important symptoms and effects, both acute and delayed : Harmful if swallowed or if inhaled.  
Causes skin irritation.  
Causes serious eye irritation.  
May cause respiratory irritation.  
May damage the unborn child. Suspected of damaging fertility.  
Causes damage to organs if swallowed.  
Causes damage to organs through prolonged or repeated exposure if swallowed.  
May cause damage to organs through prolonged or repeated exposure.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

**SECTION 5. FIRE-FIGHTING MEASURES**

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

---

Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Nitrogen oxides (NOx)
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**SECTION 7. HANDLING AND STORAGE**

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
--------------------	---	---

## Ivermectin / Abamectin Liquid Formulation

Version 7.2      Revision Date: 03.02.2025      SDS Number: 1210013-00024      Date of last issue: 30.09.2023  
 Date of first issue: 10.01.2017

- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
 Do not breathe mist or vapors.  
 Do not swallow.  
 Do not get in eyes.  
 Wash skin thoroughly after handling.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Keep container tightly closed.  
 Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers.  
 Do not eat, drink or smoke when using this product.  
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 When using do not eat, drink or smoke.  
 Wash contaminated clothing before re-use.  
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labeled containers.  
 Store locked up.  
 Keep tightly closed.  
 Keep in a cool, well-ventilated place.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents  
 Self-reactive substances and mixtures  
 Organic peroxides  
 Explosives  
 Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ivermectin	70288-86-7	TWA	30 µg/m <sup>3</sup> (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	300 µg/100 cm <sup>2</sup>	Internal
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	TWA	15 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	150 µg/100 cm <sup>2</sup>	Internal

## Ivermectin / Abamectin Liquid Formulation

Version 7.2      Revision Date: 03.02.2025      SDS Number: 1210013-00024      Date of last issue: 30.09.2023  
 Date of first issue: 10.01.2017

(dl)-a-Tocopheryl acetate	7695-91-2	TWA	5000 ug/m3 (OEB 1)	Internal
---------------------------	-----------	-----	--------------------	----------

**Biological occupational exposure limits**

Components	CAS-No.	Control parameters	Biological specimen	Sam-pling time	Permissible concentra-tion	Basis
N-Methyl-2-pyrrolidone	872-50-4	5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of shift	100 mg/l	MX BEI
		5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of shift (As soon as possible after exposure ceases)	100 mg/l	ACGIH BEI

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

**Personal protective equipment**

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Combined particulates and organic vapor type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles.  
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.  
 Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
 Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

---

Appearance	:	liquid
Color	:	light yellow
Odor	:	characteristic
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	> 100 °C
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	0.91 - 1.00 mg/l
Solubility(ies)		
Water solubility	:	insoluble
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

Molecular weight : No data available

Particle characteristics  
Particle size : Not applicable

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reactions : Can react with strong oxidizing agents.  
Conditions to avoid : None known.  
Incompatible materials : Oxidizing agents  
Hazardous decomposition products : No hazardous decomposition products are known.

**SECTION 11. TOXICOLOGICAL INFORMATION****Information on likely routes of exposure**

Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Harmful if swallowed or if inhaled.

**Product:**

Acute oral toxicity : Acute toxicity estimate: 981.33 mg/kg  
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 1.84 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg  
Method: Calculation method

**Components:****N-Methyl-2-pyrrolidone:**

Acute oral toxicity : LD50 (Rat): 4,150 mg/kg  
Method: OECD Test Guideline 401  
Remarks: The test was conducted equivalent or similar to guideline

Acute inhalation toxicity : LC50 (Rat): > 5.1 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403  
Remarks: The test was conducted according to guideline



**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

---

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg  
Method: OECD Test Guideline 402  
Remarks: The test was conducted equivalent or similar to guideline

**Ivermectin:**

Acute oral toxicity : LD50 (Rat): 50 mg/kg  
LD50 (Mouse): 25 mg/kg  
LD50 (Monkey): > 24 mg/kg  
Target Organs: Central nervous system  
Symptoms: Vomiting, Dilatation of the pupil  
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l  
Exposure time: 1 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg  
LD50 (Rat): > 660 mg/kg

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Acute oral toxicity : LD50 (Rat): 24 mg/kg  
LD50 (Mouse): 10 mg/kg  
LDLo (Monkey): 24 mg/kg  
Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0.023 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): 330 mg/kg  
LD50 (Rabbit): 2,000 mg/kg

**(dl)-a-Tocopheryl acetate:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute dermal toxicity : LD50 (Rat): > 3,000 mg/kg  
Assessment: The substance or mixture has no acute dermal toxicity

**Skin corrosion/irritation**

Causes skin irritation.

**Components:****N-Methyl-2-pyrrolidone:**

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

---

Species	:	Rabbit
Method	:	OECD Test Guideline 404
Result	:	Skin irritation
Remarks	:	The test was conducted equivalent or similar to guideline

**Ivermectin:**

Species	:	Rabbit
Result	:	No skin irritation

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species	:	Rabbit
Result	:	No skin irritation

**(dl)-a-Tocopheryl acetate:**

Species	:	Rabbit
Method	:	OECD Test Guideline 404
Result	:	No skin irritation

**Serious eye damage/eye irritation**

Causes serious eye irritation.

**Components:****N-Methyl-2-pyrrolidone:**

Species	:	Rabbit
Result	:	Irritation to eyes, reversing within 21 days
Method	:	OECD Test Guideline 405
Remarks	:	The test was conducted equivalent or similar to guideline

**Ivermectin:**

Species	:	Rabbit
Result	:	Mild eye irritation

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species	:	Rabbit
Result	:	Mild eye irritation

**(dl)-a-Tocopheryl acetate:**

Species	:	Rabbit
Result	:	No eye irritation
Method	:	OECD Test Guideline 405

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

**Components:****N-Methyl-2-pyrrolidone:**

Test Type	: Local lymph node assay (LLNA)
Routes of exposure	: Skin contact
Species	: Mouse
Method	: OECD Test Guideline 429
Result	: negative
Remarks	: Based on data from similar materials

**Ivermectin:**

Routes of exposure	: Dermal
Species	: Humans
Result	: Does not cause skin sensitization.

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Test Type	: Maximization Test
Routes of exposure	: Skin contact
Result	: Not a skin sensitizer.

**(dl)-a-Tocopheryl acetate:**

Test Type	: Draize Test
Routes of exposure	: Skin contact
Species	: Humans
Result	: negative

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative Remarks: The test was conducted according to guideline
-----------------------	---

	Test Type: In vitro mammalian cell gene mutation test Method: OECD Test Guideline 476 Result: negative Remarks: The test was conducted according to guideline
--	--

	Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Method: OECD Test Guideline 482 Result: negative Remarks: The test was conducted equivalent or similar to guideline
--	--

Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse
----------------------	--

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

---

Application Route: Ingestion  
Method: OECD Test Guideline 474  
Result: negative  
Remarks: The test was conducted according to guideline

**Ivermectin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Test system: human diploid fibroblasts  
Result: negative

Test Type: Mouse Lymphoma  
Result: negative

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

**(dl)-a-Tocopheryl acetate:**

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

**Components:****N-Methyl-2-pyrrolidone:**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 2 Years
Method	: OECD Test Guideline 451
Result	: negative
Remarks	: The test was conducted according to guideline

Species	: Rat
Application Route	: Inhalation
Exposure time	: 2 Years
Method	: OECD Test Guideline 453
Result	: negative
Remarks	: The test was conducted equivalent or similar to guideline

**Ivermectin:**

Species	: Rat
Application Route	: Oral
NOAEL	: 1.5 mg/kg body weight
Result	: negative
Remarks	: Based on data from similar materials

Species	: Mouse
Application Route	: Oral
NOAEL	: 2.0 mg/kg body weight
Result	: negative
Remarks	: Based on data from similar materials

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species	: Rat
Application Route	: Oral
Exposure time	: 105 weeks
Result	: negative

Species	: Mouse
Application Route	: Oral
Exposure time	: 93 weeks
Result	: negative

**(dl)-a-Tocopheryl acetate:**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 104 weeks
Result	: negative

**Reproductive toxicity**

May damage the unborn child. Suspected of damaging fertility.

**Components:****N-Methyl-2-pyrrolidone:**

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 416  
Result: negative  
Remarks: The test was conducted according to guideline

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 414  
Result: positive  
Remarks: The test was conducted according to guideline

Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: inhalation (vapor)  
Method: OECD Test Guideline 414  
Result: positive  
Remarks: The test was conducted equivalent or similar to guideline

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Ingestion  
Method: OECD Test Guideline 414  
Result: positive  
Remarks: The test was conducted equivalent or similar to guideline

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

**Ivermectin:**

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 0.6 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight  
Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected.

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Effects on fertility : Test Type: Fertility  
Species: Rat, male  
Application Route: Oral  
Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Early Embryonic Development: NOAEL: 0.12 mg/kg body weight  
Result: Fetotoxicity.

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Mouse  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight  
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight  
Result: Cleft palate  
Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: LOAEL: 2 mg/kg body weight  
Result: Cleft palate, Teratogenic effects., Reduced embryonic survival  
Remarks: Adverse developmental effects were observed

Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight  
Result: Teratogenic effects.

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

**(dl)-a-Tocopheryl acetate:**

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening test

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Ingestion  
Result: negative

**STOT-single exposure**

May cause respiratory irritation.

Causes damage to organs (Central nervous system) if swallowed.

**Components:****N-Methyl-2-pyrrolidone:**

Assessment : May cause respiratory irritation.

**Ivermectin:**

Target Organs : Central nervous system  
Assessment : Causes damage to organs.

**STOT-repeated exposure**

Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

**Components:****Ivermectin:**

Target Organs : Central nervous system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Routes of exposure : Ingestion  
Target Organs : Central nervous system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****N-Methyl-2-pyrrolidone:**

Species : Rat, male  
NOAEL : 169 mg/kg  
LOAEL : 433 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Method : OECD Test Guideline 408  
Remarks : The test was conducted according to guideline



**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

---

Species : Rat  
NOAEL : 0.5 mg/l  
LOAEL : 1 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 96 Days  
Method : OECD Test Guideline 413  
Remarks : The test was conducted according to guideline

Species : Rabbit, male  
NOAEL : 826 mg/kg  
LOAEL : 1,653 mg/kg  
Application Route : Skin contact  
Exposure time : 20 Days  
Method : OECD Test Guideline 410  
Remarks : The test was conducted equivalent or similar to guideline

**Ivermectin:**

Species : Dog  
NOAEL : 0.5 mg/kg  
LOAEL : 1 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Target Organs : Central nervous system  
Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey  
NOAEL : 1.2 mg/kg  
Application Route : Oral  
Exposure time : 2 Weeks  
Remarks : No significant adverse effects were reported

Species : Rat  
NOAEL : 0.4 mg/kg  
LOAEL : 0.8 mg/kg  
Application Route : Oral  
Exposure time : 3 Months  
Target Organs : spleen, Bone marrow, Kidney

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species : Rat  
NOAEL : 1.5 mg/kg  
Application Route : Oral  
Exposure time : 24 Months  
Target Organs : Central nervous system  
Symptoms : Tremors, ataxia

Species : Mouse  
NOAEL : 4.0 mg/kg  
Application Route : Oral  
Exposure time : 24 Months  
Target Organs : Central nervous system  
Symptoms : Tremors, ataxia

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

Species : Dog  
NOAEL : 0.25 mg/kg  
LOAEL : 0.5 mg/kg  
Application Route : Oral  
Exposure time : 53 Weeks  
Target Organs : Central nervous system  
Symptoms : Tremors, weight loss  
Remarks : mortality observed

Species : Monkey  
NOAEL : 1.0 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Target Organs : Central nervous system

**(dl)-a-Tocopheryl acetate:**

Species : Rat  
NOAEL : 500 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****N-Methyl-2-pyrrolidone:**

Skin contact : Symptoms: Skin irritation

**Ivermectin:**

Skin contact : Remarks: Can be absorbed through skin.  
Eye contact : Remarks: May irritate eyes.  
Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Ingestion : Symptoms: May cause, Tremors, Diarrhea, central nervous system effects, Salivation, tearing

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****N-Methyl-2-pyrrolidone:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 1,000 mg/l  
aquatic invertebrates Exposure time: 24 h

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

---

Method: DIN 38412

Remarks: The test was conducted according to guideline

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l  
Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l  
Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 12.5 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211  
Remarks: The test was conducted according to guideline

Toxicity to microorganisms : EC50 (activated sludge): > 600 mg/l  
Exposure time: 30 min  
Method: ISO 8192  
Remarks: The test was conducted according to guideline

**Ivermectin:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l  
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.000025 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l  
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l  
Exposure time: 96 h

LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l  
Exposure time: 96 h

LC50 (Cyprinus carpio (Carp)): 42 µg/l  
Exposure time: 96 h

LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

---

	Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Americamysis): 0.022 µg/l Exposure time: 96 h
	EC50 (Daphnia magna (Water flea)): 0.34 µg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l Exposure time: 32 d
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0.03 µg/l Exposure time: 21 d
	NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l Exposure time: 28 d
Toxicity to microorganisms	: EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition
<b>(dl)-a-Tocopheryl acetate:</b>	
Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
	NOEC (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic toxicity)	: NOEC (Oncorhynchus mykiss (rainbow trout)): 100 mg/l Exposure time: 28 d
Toxicity to microorganisms	: EC50: > 927 mg/l Exposure time: 30 min Method: ISO 8192

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

**Persistence and degradability****Components:****N-Methyl-2-pyrrolidone:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 73 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301C  
Remarks: The test was conducted according to guideline

**Ivermectin:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 240 d

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Stability in water : Hydrolysis: 50 %(< 12 h)

**(dl)-a-Tocopheryl acetate:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 21.7 - 31 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301C

**Bioaccumulative potential****Components:****N-Methyl-2-pyrrolidone:**

Partition coefficient: n-octanol/water : log Pow: -0.46  
Method: OECD Test Guideline 107  
Remarks: The test was conducted according to guideline

**Ivermectin:**

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water : log Pow: 3.22

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-octanol/water : log Pow: 4

**Mobility in soil****Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Distribution among environmental compartments : log Koc: > 3.6

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

**Other adverse effects**

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)
Class	:	9
Packing group	:	III
Labels	:	9
Environmentally hazardous	:	yes

**IATA-DGR**

UN/ID No.	:	UN 3082
Proper shipping name	:	Environmentally hazardous substance, liquid, n.o.s. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)
Class	:	9
Packing group	:	III
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	964
Packing instruction (passenger aircraft)	:	964
Environmentally hazardous	:	yes

**IMDG-Code**

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)
Class	:	9
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

**Domestic regulation****NOM-002-SCT**

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)
Class	:	9
Packing group	:	III
Labels	:	9

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills. : Not applicable

**The ingredients of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

**SECTION 16. OTHER INFORMATION**

Revision Date	:	03.02.2025
Date format	:	dd.mm.yyyy

**Full text of other abbreviations**

ACGIH BEI	:	ACGIH - Biological Exposure Indices (BEI)
MX BEI	:	Official Mexican Norm NOM-047-SSA1-2011, Environmental Health - Biological exposure indices for workers occupationally exposed to chemical agents

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.2	03.02.2025	1210013-00024	Date of first issue: 10.01.2017

---

- International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8